Study on Hemostimulating Properties of Granulocyte-Macrophage Colony Stimulating Factor

The hemostimulating properties of granulocyte-macrophage colony-stimulating factor (GM-CSF) make possible its clinical use in alleviating side effects of anti-cancer radio- and chemotherapy, in bone marrow transplantation, and in the treatment of some primary immunodeficiency conditions associated with leukopenia. The State Research Center of Virology and Biotechnology “Vector” of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing has developed a high-performance technology for production of recombinant human GM-CSF (rhGM-CSF) based on a recombinant E. coli strain. The aim of the study was to assess hemostimulating activity of the rhGM-CSF preparation obtained using the new developed technology, as observed in cell culture and in the mice model of myelosuppression induced by cyclophosphamide administration. Materials and methods: in vitro evaluation of rhGM-CSF hemostimulating activity was performed by MTT assay in the commercial HL-60 promyelocytic leukemia cell culture with preliminary suppression of cell growth rate by adding a low concentration of dimethyl sulfoxide to the medium. In vivo studies were carried out in CBA/CaLac mice with cyclophosphamide-induced myelosuppression. The hemostimulating properties of the drug were evaluated after subcutaneous administration of 1–175 µg/kg doses for 4–5 days, following administration of a cytostatic agent. The total number of leukocytes and the content of their morphological forms were determined in blood samples taken at different time points after the drug administration. The statistical processing of the experimental data was based on analysis of variance using Statgraphics v. 5.0 software. Results: the proliferative activity of HL-60 cells incubated with the rhGM-CSF preparation for 72 hours was shown to be dose-dependent. The highest values of the increase in proliferative activity associated with an increase in the drug dose were observed in the concentration range from 0.04 to 0.64 ng/mL (proliferative activity increased by 11–18% when the dose was increased twofold). The experiments in mice demonstrated a two-phase pattern of the dose-dependent effect. The drug showed the highest hemostimulating effect at the dose of 90 µg/kg. Conclusions: the rhGM-CSF preparation obtained using the new developed technology has a pronounced hemostimulating activity confirmed by both in vitro and in vivo test systems. 

1. Bagrova SG. Granulocyte colony-stimulating factors in prevention of febrile neutropenia. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2015;(31):6–15 (In Russ.)

2. Maltsev DV. Indications for the use of colony-stimulating factors in clinical practice. Klinicheskaya immunologiya. Allergologiya. Infektologiya = Clinical Immunology. Allergology. Infectology. 2018;(1):5–12 (In Russ.)

3. Polovinkina VS, Kosorukov VS. Recombinant hGM-CSF in antitumor therapy. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy. 2009;8(1):29–39 (In Russ.)

4. Gazatova ND, Meniailo ME, Malashchenko VV, Goncharov AG, Melashchenko OB, Morozova EM, Seledtsov VI. Direct effects of GM-CSF on the functions of human monocytes/macrophages. Meditsinskaya immunologiya = Medical Immunology (Russia). 2019;21(3):419–26 (In Russ.) https://doi.org/10.15789/1563-0625-2019-3-419-426

5. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol. 2000;7(3):168–73. https://doi.org/10.1097/00062752-200005000-00007

6. Belogurova MB. Clinical use of hematopoietic growth factors. Prakticheskaya onkologiya = Practical Oncology. 2003;4(3):183–90 (In Russ.)

7. Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, et al. Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor. Med Oncol. 2014;31(1):774. https://doi.org/10.1007/s12032-013-0774-6

8. Libby RT, Braedt G, Kronheim SR, March CJ, Urdal DL, Chiaverotti SR, et al. Expression and purification of native human granulocyte-macrophage colony-stimulating factor from an Escherichia coli secretion vector. DNA. 1987;6(3):221–9. https://doi.org/10.1089/dna.1987.6.221

9. Delamarter J, Ernst JF. Human granulocyte-macrophage colony stimulating factor-like polypeptides and process for producing them in high yields in microbial cells. WO1987002060. 1987.

10. Esina TI, Lebedev LR, Volosnikova EA, Gileva IP, Gogina YaS, Tereshchenko TA, et al. Method for obtaining recombinant human granulocyte-macrophage colony-stimulating factor. Biotekhnologiya = Biotechnology. 2019;35(3):68–73 (In Russ.) https://doi.org/10.21519/0234-2758-2019-35-3-68-73

11. Gileva IP, Esina TI, Volosnikova EA, Gogina YaS, Lebedev LR, Danilenko ED. Recombinant plasmid DNA p280_2GM coding polypeptide with properties of granulocyte-macrophage colony-stimulating factor of human, strain Escherichia coli SG 20050/p280_2GM — producer of polypeptide with properties of granulocyte-macrophage colony-stimulating factor of human and method of obtaining of said polypeptide. Patent of the Russian Federation № 2708556; 2019 (In Russ.)

12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54. https://doi.org/10.1006/abio.1976.9999

13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–5. https://doi.org/10.1038/227680a0

14. Yamaguchi T, Yamaguchi T, Kogi M, Yamamoto Y, Hayakawa T. Bioassay of human granulocyte colony-stimulating factor using human promyelocytic HL-60 cells. Biol Pharm Bull. 1997;20(9):943–7. https://doi.org/10.1248/bpb.20.943

15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63. https://doi.org/10.1016/0022-1759(83)90303-4

16. Masycheva BI, Danilenko ED, Shimina GG, Gvozdeva TS, Alyamkina EA, Dolgova EV, et al. Study of hemostimulating activity of nucleoprotein complex extracted from the human placenta. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology. 2012;(5):34–8 (In Russ.)

17. Novitskiy VV, Evtushenko OM. A guide to practical studies on hematology. Tomsk: Siberian Medical University; 1999 (In Russ.)

18. Grjibovsky AM. Analysis of three and more independent groups quantitative data. Ekologiya cheloveka = Human Ecology. 2008;(3):50–8 (In Russ.)

19. Grazhdantseva AA, Sivolobova GF, Tkacheva AV, Gileva IP, Kuligina EV, Rikhter VA, Kochneva GV, et al. Highly effective production of biologically active, secreted, human granulocyte macrophage colony-stimulating factor by recombinant vaccinia virus. Biotekhnologiya = Biotechnology. 2015;31(5):13–21 (In Russ.)

20. Veselovsky VA, Veselova TV, Chernavsky DS. Three-phase (paradoxical) dose-dependent response of a plant cell to environmental factors. Rossiyskiy khimicheskiy zhurnal = Russian Journal of General Chemistry. 1999;43(5):49–54 (In Russ.)

21. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226–32. https://doi.org/10.1093/annonc/mdl158

22. Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, et al. GM-CSF quantity has a selective effect on granulocytic vs. monocytic myeloid development and function. Front Immunol. 2018;9:1922.